The agency published a docket this morning opening a 60-day comment period. We break down the timeline, the three likely outcomes, and how it affects vendors currently operating in the gap.
The revised list moves two GLP-1 agonists off shortage status, triggering a wind-down clock for compounders.
A recognized lab flagged endotoxin levels above spec on lots shipped in Q2. Full statement links off-site.
We read every cited paper so you don’t have to — sample sizes, endpoints, and what’s still unknown.
Aggregate verification data from the community, with the vendors whose lots matched labels most often.
Enforcement action names marketing claims as the trigger. Original notice published elsewhere.
“Logged an 8-week protocol for a nagging tendon issue. Sharing my exact numbers and the COA for the lot I used.”
“No dramatic before/after here — just honest notes on sleep and skin over 6 weeks. Your results will vary.”
Guided journeys for founders and affiliates — sourcing, payment processing, and published commission structures. Choose your path and we'll walk you through it.
Regulatory moves, new COAs, and vendor changes. No hype, no affiliate spam.